Cargando…
Sustained-Release Vildagliptin 100 mg in Type 2 Diabetes Mellitus: A Review
Dipeptidyl peptidase-4 inhibitors (DPP4Is) were introduced into the management of type 2 diabetes mellitus (T2DM) as they are insulinotropic and have no inherent risk of hypoglycemia and no effect on body weight. Currently, 11 drugs in this class are available for the management of diabetes. Althoug...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10291938/ https://www.ncbi.nlm.nih.gov/pubmed/37378205 http://dx.doi.org/10.7759/cureus.39204 |
_version_ | 1785062784075038720 |
---|---|
author | Sridhar, GR Pandit, Kaushik Warrier, Sona Birla, Ashish |
author_facet | Sridhar, GR Pandit, Kaushik Warrier, Sona Birla, Ashish |
author_sort | Sridhar, GR |
collection | PubMed |
description | Dipeptidyl peptidase-4 inhibitors (DPP4Is) were introduced into the management of type 2 diabetes mellitus (T2DM) as they are insulinotropic and have no inherent risk of hypoglycemia and no effect on body weight. Currently, 11 drugs in this class are available for the management of diabetes. Although they have a similar mechanism of action, they differ from one other in their binding mechanisms, which influences their therapeutic and pharmacological profiles. Vildagliptin's overall safety and tolerability profile was comparable to placebo throughout clinical studies, and real-world data in a large group of T2DM patients corroborated this finding. Therefore, DPP4Is like vildagliptin is a secure alternative for treating patients with T2DM. Vildagliptin treatment given as a once-daily (QD) 100 mg sustained release (SR) formulation fits the criteria of adherence and compliance. This SR formulation, given once daily has the potential to provide glycemic control like the vildagliptin 50 mg twice-daily (BD) formulation. This comprehensive review discusses the journey of vildagliptin as 50 mg BD therapy as well as 100 mg SR QD therapy. |
format | Online Article Text |
id | pubmed-10291938 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-102919382023-06-27 Sustained-Release Vildagliptin 100 mg in Type 2 Diabetes Mellitus: A Review Sridhar, GR Pandit, Kaushik Warrier, Sona Birla, Ashish Cureus Endocrinology/Diabetes/Metabolism Dipeptidyl peptidase-4 inhibitors (DPP4Is) were introduced into the management of type 2 diabetes mellitus (T2DM) as they are insulinotropic and have no inherent risk of hypoglycemia and no effect on body weight. Currently, 11 drugs in this class are available for the management of diabetes. Although they have a similar mechanism of action, they differ from one other in their binding mechanisms, which influences their therapeutic and pharmacological profiles. Vildagliptin's overall safety and tolerability profile was comparable to placebo throughout clinical studies, and real-world data in a large group of T2DM patients corroborated this finding. Therefore, DPP4Is like vildagliptin is a secure alternative for treating patients with T2DM. Vildagliptin treatment given as a once-daily (QD) 100 mg sustained release (SR) formulation fits the criteria of adherence and compliance. This SR formulation, given once daily has the potential to provide glycemic control like the vildagliptin 50 mg twice-daily (BD) formulation. This comprehensive review discusses the journey of vildagliptin as 50 mg BD therapy as well as 100 mg SR QD therapy. Cureus 2023-05-18 /pmc/articles/PMC10291938/ /pubmed/37378205 http://dx.doi.org/10.7759/cureus.39204 Text en Copyright © 2023, Sridhar et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Endocrinology/Diabetes/Metabolism Sridhar, GR Pandit, Kaushik Warrier, Sona Birla, Ashish Sustained-Release Vildagliptin 100 mg in Type 2 Diabetes Mellitus: A Review |
title | Sustained-Release Vildagliptin 100 mg in Type 2 Diabetes Mellitus: A Review |
title_full | Sustained-Release Vildagliptin 100 mg in Type 2 Diabetes Mellitus: A Review |
title_fullStr | Sustained-Release Vildagliptin 100 mg in Type 2 Diabetes Mellitus: A Review |
title_full_unstemmed | Sustained-Release Vildagliptin 100 mg in Type 2 Diabetes Mellitus: A Review |
title_short | Sustained-Release Vildagliptin 100 mg in Type 2 Diabetes Mellitus: A Review |
title_sort | sustained-release vildagliptin 100 mg in type 2 diabetes mellitus: a review |
topic | Endocrinology/Diabetes/Metabolism |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10291938/ https://www.ncbi.nlm.nih.gov/pubmed/37378205 http://dx.doi.org/10.7759/cureus.39204 |
work_keys_str_mv | AT sridhargr sustainedreleasevildagliptin100mgintype2diabetesmellitusareview AT panditkaushik sustainedreleasevildagliptin100mgintype2diabetesmellitusareview AT warriersona sustainedreleasevildagliptin100mgintype2diabetesmellitusareview AT birlaashish sustainedreleasevildagliptin100mgintype2diabetesmellitusareview |